S-1 + nedaplatin

S-1 + nedaplatin is a combination chemotherapy regimen consisting of two agents: - **S-1** is an oral fluoropyrimidine derivative composed of tegafur (a prodrug of 5-fluorouracil), gimeracil (an inhibitor of dihydropyrimidine dehydrogenase to increase 5-FU bioavailability), and oteracil potassium (to reduce gastrointestinal toxicity). It acts primarily as an antimetabolite by inhibiting DNA synthesis in rapidly dividing tumor cells. - **Nedaplatin** is a second-generation platinum-based chemotherapeutic agent. It forms DNA cross-links, leading to apoptosis and cell death. Nedaplatin was developed to have similar efficacy but reduced nephrotoxicity and gastrointestinal toxicity compared to cisplatin. This combination has been studied for the treatment of various squamous cell carcinomas, including head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC) with squamous histology, and nasopharyngeal carcinoma. The typical administration involves oral S-1 for 14 days combined with intravenous nedaplatin on day 1 or day 8 in a three-week cycle[2][3][4][5]. The regimen aims to provide effective cytotoxic therapy with improved tolerability over traditional platinum/fluoropyrimidine combinations.

Other names

S-1 and nedaplatinS1 and nedaplatinS 1 and nedaplatinnedaplatin plus S-1NS regimen